A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.

// Gui-Qi Zhu 1,2,* , Ke-Qing Shi 1,3,* , Gui-Qian Huang 1,4 , Li-Ren Wang 1,2 , Yi-Qian Lin 1,4 , Martin Braddock 5 , Yong-Ping Chen 1,3 , Meng-Tao Zhou 6 and Ming-Hua Zheng 1,3 1 Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China 2 School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China 3 Institute of Hepatology, Wenzhou Medical University, Wenzhou China 4 Renji School of Wenzhou Medical University, Wenzhou China 5 Global Medicines Development, AstraZeneca RD MD -484.34, P < 0.001; respectively). With respect to POLHS, although differing not significantly, UDCA plus MTZ had a tendency to improve LHS more than UDCA (OR 1.33), UDCA plus MMF (OR 3.24) or OBS (OR 1.08). Additionally, UDCA plus MTZ (MD -544.66, P < 0.001) showed a significant reduction in ALP levels compared with OBS, but appeared to be associated with more AEs compared with UDCA (OR 5.09), UDCA plus MMF (OR 4.80) or OBS (OR 7.21). Conclusions: MTZ plus UDCA was the most effective therapy in survival rates and liver histological progression.